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Abstract 
Pneumonia remains a global health priority in children. It is the leading cause of death in children outside the 
neonatal period, over 90% of which occur in low-resource settings, and a major cause of morbidity, 
accounting for over 100 million episodes globally each year. Early, correct diagnosis is a modifiable factor 
which can potentially improve pneumonia outcomes. Current guidelines recommend the use of clinical signs 
and symptoms alone to make a diagnosis of pneumonia in low risk, ambulatory cases with clinically mild 
disease. However, clinical diagnosis lacks specificity and may lead to antibiotic overuse and drive antibiotic 
resistance. Addition of chest X-ray (CXR) to diagnostic algorithms improves specificity, but CXR use is limited 
by radiation exposure and relatively high costs, limiting access in low-resource settings. Current guidelines 
therefore reserve CXR for moderate to severe disease and hospitalised cases, even in well-resourced settings. 
Lung ultrasound (LUS) is a promising imaging modality which uses no radiation, is less costly than CXR and 
can improve the time to results when used as a point-of-care tool by clinicians outside the radiology 
department. These characteristics make LUS, at least theoretically, a potential option either as add-on 
screening test aimed at decreasing unnecessary antibiotic prescription or as a lower risk, lower cost definitive 
diagnostic test capable of replacing CXR, or both. The objective of this study was to understand the role of 
LUS as a diagnostic test for pneumonia in children by performing a structured literature review and meta-
analysis summarizing the current evidence comparing diagnostic performance of LUS and CXR, and by 
reporting previously unpublished data from the Drakenstein Child Health Study comparing diagnostic 
performance of LUS and CXR for pneumonia in children in a resource-constrained, African setting. 
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Author: Dr Jacob A M Stadler 
Version & Date: Version 1.0 (Dated: 20 Jun 2018) 
Background and significance 
Pneumonia and other forms of lower respiratory tract infections (LRTI) remain the leading causes of 
death and a major causes of morbidity in children under 5 years of age, accounting for 13-20% of 
childhood deaths globally, despite advances in prevention and treatment strategies such as 
expansion of routine childhood vaccinations and strong prevention of mother to child HIV 
transmission programs1. The incidence of pneumonia remains high2 but early, correct diagnosis and 
treatment can improve pneumonia outcomes in young children.  
Prominent evidence-based guidelines for management of pneumonia in children consider the 
condition to be primarily a clinical diagnosis based on a typical symptom history and presence of 
clinical signs. These guidelines therefore recommend against routine use of chest X-ray (CXR) 
imaging when uncomplicated community-acquired pneumonia is suspected3–5. This 
recommendation is based mainly on evidence suggesting that CXR does not significantly impact 
pneumonia outcomes in these cases6. However, clinical signs and symptoms have also been shown 
to have limited diagnostic accuracy7. Clinicians therefore still prefer the use of imaging tests to 
confirm their clinical diagnosis despite these guidelines8. There are also many scenarios where CXR 
imaging is recommended to aid in the diagnosis and management of more complicated pneumonia 
cases3–5. CXR therefore is currently the most frequently performed imaging test for diagnosing LRTI 
in children. 
Despite its wide use, several well recognised factors limit the usefulness of CXR as a diagnostic tool 
for LRTI, most importantly the relatively poor accuracy and reliability when interpreting imaging 
results9–14. CXR can therefore by no means be considered a gold standard for pneumonia diagnosis. 
Access to CXR imaging is also limited in many settings due to the regulatory requirements, expertise 
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and cost necessary to run a radiology service. This is particularly import as the vast majority of 
pneumonia deaths occur in low and middle-income countries2. The perception of increased risk of 
malignancy associated with ionising radiation exposure, especially in young children, is also often 
used to discourage routine use of CXRs, despite limited evidence for this argument15,16. 
Ultrasound has historically been viewed as unsuitable for visualisation of the lungs for two reasons: 
the air in healthy lung tissue scatters the ultrasound waves which makes direct visualisation of air-
filled lung parenchyma and deep lung structures with ultrasound impossible; secondly, much of the 
lung surface is covered by calcified bone of the thoracic cage which is impenetrable to ultrasound. 
However, many disease processes in the lung tend to increase the extravascular fluid component of 
lung tissue and when severe, affected areas of the lung become consolidated, with alveolar air being 
displaced by fluid. In other cases, lung disease gives rise to pleural pathology such as pleural effusion 
or pneumothorax. It has long been recognised that these areas of diseased lung give rise to distinct 
ultrasound patterns not present in normal lungs17,18. This means that ultrasound can be used to 
discriminate healthy from unhealthy lungs and describe different types of lung pathology. Early 
studies of lung ultrasound (LUS) evaluated its usefulness in dyspnoeic adults in intensive care 
settings and showed good accuracy of certain sonographic patterns for detecting certain types of 
lung pathology when compared against a gold standard of computed tomography (CT) scans19. 
Since then a growing body of evidence has surfaced suggesting that the diagnostic performance of 
LUS may be similar if not better than CXR for detecting evidence of LRTI20,21. LUS has also gained 
popularity for several reasons other than its diagnostic accuracy, most importantly the fact that it is 
radiation free, which makes it ideal for use in the paediatric population, which also represent the 
highest pneumonia risk group. This absence of radiation, combined with the development of newer, 
portable ultrasound devices means it can be used outside of the radiology department by non-
radiologists, a feature which holds significant promise in resource constrained settings where access 
to radiology services are limited or as a screening tool in a variety of primary care settings which 
could potentially lead to decreased use of CXR, especially in children. 
Despite its growing popularity, implementation in clinical practice has been slow and LUS has not 
yet been included as alternative to CXR in major evidence-based pneumonia management 
guidelines. This may be due to certain limitations of LUS and some significant questions regarding 
its role in the management of childhood LRTI which have not yet been fully clarified. Much like CXR, 
LUS has been shown to be an imperfect diagnostic tool which will miss lung consolidations not 
extending to the pleura or in areas obstructed by bony structures such as the scapulae22–25. There is 
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also recognition in current literature that image quality and interpretation of scans are user-
dependent and questions regarding adequate training, equipment specifications and standardized 
terminology remain26–29. 
The number of studies assessing the diagnostic accuracy of lung ultrasound in children are limited 
and even fewer such studies have been done outside of a developed world context and academic 
environments. Further, these studies most frequently include children treated in hospital rather 
than in a primary care setting and LUS are frequently performed by expert sonographers rather than 
primary care clinicians20,21. These factors limit the external validity of findings on the diagnostic 
performance of LUS to diverse real-world situations. Methodology used in these studies is also fairly 
heterogenous and often do not adhere to good reporting guidelines which makes comparison of 
results across studies difficult30. 
We propose a study to better understand the role of LUS as a diagnostic tool for childhood LRTI, 
both in a primary care and in-hospital setting. To do this we plan to analyse data from a series of 
LRTI cases from the Drakenstein Child Health Study, a multi-year birth cohort study conducted in 
Paarl, South Africa, which investigates the early life determinants of lung health. We will describe 
findings and compare the diagnostic performance of LUS, performed by a general practitioner with 
basic training, to CXR images, the current standard of care, in a cohort of African children presenting 
with both ambulatory and hospitalised episodes of suspected LRTI.  
Objectives & Aims 
The primary objective of this study is to compare the diagnostic performance (validity and reliability) 
of LUS with that of CXR for diagnosing pneumonia in children who present with clinical symptoms 
and signs of LRTI. 
Specific aims: 
1. To describe the type and frequency of CXR and LUS findings in a series of clinically defined
pneumonia cases from the Drakenstein Child Health Study.
2. To compare the diagnostic performance of LUS and CXR for diagnosis of pneumonia by means
of:
• Sensitivity and specificity, using CXR as reference standard
• Concordance (inter-test agreement) between LUS and CXR
• Comparing inter-observer agreement (reliability) between LUS and CXR
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Methods 
We plan to perform secondary analysis of previously collected data.  Data collection was performed 
under protocol of the primary study which has received ethics approval (Drakenstein Child Health 
Study, UCT-HREC #: 401/2009). Described below is the methodology and data analysis plan for our 
proposed analysis. We also outline relevant methodology used by the primary study during 
collection of the data. 
• Study Design, Setting & Population
The primary study is a multi-year birth cohort which enrolled 1225 pregnant women (leading to 
1143 live births) between 2012 - 2015 from two public sector primary health clinics in Paarl, a town 
with a population of approximately 200000 people, in the Drakenstein district of the Western Cape 
province, approximately 50km from Cape Town. The cohort of mother-infant dyads is currently in 
its sixth year of follow-up. 
The study population can broadly be divided into two distinct peri-urban communities based on the 
drainage area for the two enrolment clinics: Mbekweni clinic serving a predominantly Black African 
township population (680 mothers) and TC Newman clinic serving a predominantly mixed-race 
population (545 mothers). Both communities are characterised by high prevalence of 
unemployment, poverty and related social determinants of health as well as a high burden of 
infectious diseases including TB and HIV. 
We propose to conduct a secondary analysis of data collected by the Drakenstein Child Health Study 
between Aug 2014 - Dec 2015. The analysis will be a cross-sectional (at the time of LRTI diagnosis) 
diagnostic accuracy study of a prospectively observed series of clinically defined cases of suspected 
LRTI occurring in infant participants. 
• Sampling, Participant Selection & Recruitment
The primary study enrolled participants attending antenatal care at the two facilities described 
above using convenience sampling. Inclusion criteria for pregnant women in the primary study were 
as follows: 18 years or older; between 20-28 weeks gestation at enrolment; at the time of enrolment 
not planning to relocate out of the area for a least a year following enrolment; willing and able to 
consent to study participation. There were no specific exclusion criteria. 
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Inclusion into the proposed secondary analysis will be based on occurrence of LRTI episodes and the 
availability of CXR and LUS data collected around the time of diagnosis. Cases where imaging were 
performed >72 hours from the date of diagnosis or where the CXR and LUS were performed >72 
hours apart, will excluded from the analysis, as delayed imaging by either modality may affect 
accuracy measures. 
• Study Procedures & Outcome Measures
As part of the primary study the mother-infant dyads where followed up during several scheduled 
antenatal and post-natal study visits to record baseline health and risk factor data. Following 
delivery, active surveillance by study staff through regular surveillance rounds at public health 
facilities in the district and passive surveillance in the form of a 24-hour study hotline was used to 
identify any symptomatic infants suspected of having a LRTI. Symptomatic infants where then 
assessed within 24 hours by clinically trained study staff to determine if diagnostic criteria for LRTI 
were present.  
A clinical diagnosis of LRTI was made based on World Health Organisation (WHO) clinical pneumonia 
case definition. Infants with clinically confirmed LRTI then received a full clinical evaluation and a 
lung ultrasound performed by a trained study clinician within 72hrs from diagnosis. A CXR was 
performed at diagnosis for most infants who were hospitalised with LRTI as part of routine care as 
well as for some infants receiving outpatient care, as deemed necessary by the treating clinicians. 
Additional data relating to risk factors, clinical presentation, severity, management and outcomes 
were also recorded at the time of diagnosis, as well as at a 2-3 day and again at 4-6 weeks follow-
up visits, when ultrasound was also repeated. 
LUS and CXR images performed at pneumonia diagnosis were reported by two separate reporters 
for each imaging modality. CXR were reported by two specialist paediatricians and findings were 
classified using the WHO Pneumonia Working Group standardised interpretation method for 
pneumonia in children. Lung ultrasound images where reported by a trained general practitioner 
(unblinded study clinician performing the scan) as well as a blinded expert paediatric radiologist 
using a classification system based on current literature with diagnostic categories compatible 
(representing similar disease processes) to those used for CXR. Findings from CXR and LUS 
performed on the same infant during the same pneumonia episode are then compared. 
The proposed secondary analysis only involves statistical analysis of previously collected data only 
and therefore no new study procedures will be conducted. 
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• Sample Size & Statistical Analysis Plan
Descriptive analysis will be done using medians and inter-quartile ranges (IQR) for continuous 
variables, while categorical variables will be summarized using frequencies and percentages.  
Comparison of inter-observer agreement (reliability) as well as agreement between LUS and CXR 
(inter-test agreement) will be performed using appropriate measures of agreement (direct 
agreement indexes and Kappa-coefficients). Traditional accuracy measures such as sensitivity, 
specificity and positive and negative predictive values are not considered meaningful in the absence 
of a definitive gold standard. For the diagnosis of pneumonia, CT scan demonstration of air-space 
consolidation is probably the one imaging method which can be considered a diagnostic gold 
standard, but its use is not ethically feasible in mild to moderate paediatric pneumonia. We will 
therefore consider appropriate ‘absent gold standard’ methods to assess and compare diagnostic 
accuracy (validity).  
The size of the available sample for this analysis is dependent on availability of data from the primary 
study, and as such prior sample size calculation was not performed. However, we performed sample 
size calculations for inter-rater agreement (Cohen’s Kappa) which determined that a sample of 61 
cases would be required at a significance level of 0.05 and 80% statistical power, with expected 
agreement for CXR set at Kappa=0.55 and for LUS at Kappa=0.80 and expected true prevalence of 
lung consolidation, interstitial disease picture and normal imaging findings to be 35%, 40% and 25% 
respectively (expected values based on prior literature). We therefore conclude that the available 
study sample of approximately 100 cases provides adequate power for detecting the expected 
difference in agreement (Kappa-coefficients) for the two imaging modalities when reported by two 
independent readers using the described three outcome categories. 
Statistical analysis will be performed using STATA version 14 statistical software package. Sample 
size calculations was performed using R statistical software (kappaSize package). 
Ethical Considerations 
• Informed consent
For the primary study all participants signed informed consent at enrolment and again annually in a 
language of their choice. This included consent for primary data collection, sharing and storage and 
publication of results, therefore no additional consent will be sought for this secondary data 
analysis. Infants in the primary study are currently still under 6 years of age, therefore assent was 
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not sought. A copy of the primary study informed consent form is included in this application 
(Appendix B). 
• Participant safety
The proposed research only involves secondary analysis of previously collected data which holds no 
direct safety risk to participants.  
The primary study is purely observational and does not aim to influence the outcomes of 
participants, however any clinically significant findings identified during study visits or procedures 
are referred for appropriate care by study staff according to standard referral pathways within the 
local public health care system. This included any LUS, CXR or clinical examination findings to be 
used in the proposed analysis, deemed clinically relevant at the time by the study clinician. Where 
required, these findings were immediately made available to treating clinicians to potentially assist 
with diagnosis and management of LRTI cases.  
Ionising radiation (X-rays) theoretically carries a dose-related increase in risk of later-life malignancy, 
although the risk from standard radiographs is generally considered extremely low and acceptable 
for diagnostic use in the context of children hospitalised with suspected LRTI. In view of this 
theoretical risk, the primary study protocol did not require CXR imaging to be done for suspected 
LRTI cases, but only required collection and reporting of CXR images performed if requested by 
treating clinicians, based on their clinical judgement.  
Ultrasound is not known to carry any risks to humans, which forms part of the rationale for 
conducting this study, as it may potentially offer a better risk-benefit ratio than X-ray imaging. 
During the ultrasound procedure cold jelly is applied to the skin of the infant which may cause mild 
discomfort and anxiety in the infant, but typically do not persist beyond the duration of the 
procedure.   
• Privacy, Confidentiality & Database Protection
Only anonymized data will be made available by the primary study for this analysis and the data will 
be stored on a password protected computer. Risks related to the use of personal data are therefor 
considered no more than minimal.  
• Benefits of study participation
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There are no direct benefits for participants to be included in the proposed research. There may be 
future, indirect benefit for participants and the general paediatric population from the knowledge 
generated by this research. 
• Compensation for study participation
Secondary data is used, therefore reimbursement for participants are not applicable. 
• Insurance
The planned secondary data analysis poses no direct risk of bodily harm and no more than minimal 
data-related risk, therefore insurance or indemnity cover of any kind for the investigators or the 
University are not considered necessary. 
• Inclusion of vulnerable populations
This protocol only involves secondary data analysis of previously collected data. The primary study 
has ethics approval for research involving minors. 
• Post-trial treatment
Although data collection by the primary study involved a clinical intervention (LUS), the study design 
was observational in nature, and as such secondary analysis of this data will not be able to 
conclusively and exhaustively determine whether LUS is superior to the standard of care (CXR). It 
would therefore not be appropriate to recommend post-study intervention based on the findings 
of the proposed research alone. 
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PART 2: Literature Review
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OBJECTIVES AND AIMS 
The objective of this literature review was to understand the role of lung ultrasound (LUS) as a diagnostic 
imaging tool for pneumonia in children, and to summarise current literature comparing the diagnostic 
accuracy of LUS to chest X-ray (CXR).  
Specific aims: 
1. To review lung ultrasound methodology and applications in children with suspected pneumonia by
identifying and summarising aspects, including:
▪ Equipment used, imaging techniques, training requirements, and clinical settings where LUS in
children is used.
▪ The type and frequency of sonographic findings associated with pneumonia, diagnostic
definitions used and classification of results.
▪ Considerations (strengths and limitations) other than accuracy, including safety profile, cost and
time-efficiency relative to other imaging modalities.
2. To summarise current evidence of the diagnostic accuracy of LUS compared to CXR for detecting
pneumonia in children and explore methodological factors influencing accuracy.
3. To critically appraise the quality of evidence current literature and identify areas requiring further
study.
SEARCH STRATEGY AND STUDY SELECTION 
An electronic Pubmed Medline database search was done for English language publications from inception 
to 31 December 2018. Search terms used, and search results are summarised in the table below:  
Search Nr Search Terms Nr of results 
#1 paediatric OR paediatrics OR childhood OR children OR child 2606173 
#2 
pneumonia OR (lung infection) OR (lower respiratory tract infection) OR LRTI OR (chest infection) 
OR (respiratory infection) OR bronchiolitis 
487779 
#3 lung OR pulmonary OR chest OR thorax OR thoracic 1571106 
#4 ultrasound OR ultrasonography OR sonography OR sonographic OR sonar 1483116 
#5 #1 AND #2 AND #3 AND #4 4805 
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Full search terms used in PubMed (MEDLINE): 
((((paediatric OR paediatrics OR childhood OR children OR child)) AND (pneumonia OR (lung infection) OR (lower 
respiratory tract infection) OR LRTI OR (chest infection) OR (respiratory infection) OR bronchiolitis)) AND (lung OR 
pulmonary OR chest OR thorax OR thoracic)) AND (ultrasound OR ultrasonography OR sonography OR sonographic 
OR sonar) 
Titles and abstracts were screened to identify observational or interventional studies evaluating the 
diagnostic accuracy of LUS. Of these, all studies comparing, directly or indirectly, the diagnostic performance 
of LUS to CXR in children presenting with suspected lower respiratory tract infection of any form (including 
bronchiolitis), were included. A further manual search of the reference lists of included studies were 
performed to identify any additional studies not identified during the database search. Final selection criteria 
were as follows: 
Inclusion criteria: 
1. The study population was children (<21 years) presenting for care with clinical signs and symptoms
of lower respiratory tract infection, i.e. it could be considered reasonable to perform imaging studies
for suspected pneumonia.
2. Participants received both LUS and CXR around the time of symptomatic presentation to care, thus
allowing for comparison of paired LUS and CXR results, either directly by using CXR as reference
standard or indirectly by using a reference standard other than CXR, with LUS as index test and CXR
as comparator test.
3. LUS and CXR results were reported as positive or negative for the presence of pneumonia, or
sufficient details of radiographic and sonographic findings were reported to allow re-classification of
results as positive or negative for pneumonia based on the presence or absence of either
consolidation or interstitial disease picture or both.
Exclusion criteria: 
1. Insufficient information reported to construct a 2x2 table indicating the number of true positive (TP),
false positive (FP), true negative (TN) and false negative (FN) cases required to calculate diagnostic
accuracy (sensitivity and specificity)
2. Studies focussed on diagnosis of conditions other than acute lower respiratory tract infection
(pneumonia or bronchiolitis).
3. Studies focussed primarily on mediastinal ultrasound.
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INTRODUCTION 
 Childhood pneumonia: pathology, aetiology and epidemiology 
Lower respiratory tract infection (LRTI) is a spectrum of disease affecting the lungs that ranges from 
bronchiolitis to pneumonia. In the pre-vaccination era, bacterial pathogens such as Streptococcus 
pneumoniae and Heamophilus influenzae were the most frequently implicated pathogens in severe 
pneumonia1, but more recent aetiology studies equally implicate both viruses and bacteria2,3. In severe cases, 
air-space in the lungs become fluid-filled (consolidated) due to the inflammatory process. When large 
enough, these areas of consolidation are visible on chest radiographs and can be used to confirm the 
diagnosis of pneumonia. Despite a steady decline in mortality in recent decades, pneumonia remains the 
leading cause of death and a major cause of morbidity in children under 5 years old, neonatal period 
excluded, accounting for an estimated 102 million episodes and 704000 deaths globally in 20154,5. 
Pneumonia outcomes are strongly associated with poverty-related determinants of health such as 
malnutrition and access to and quality of healthcare, with an estimated burden of 72 deaths / 100000 
population in low-income settings compared to only 1.7 / 100000 in high-income settings5. In South Africa 
the incidence of pneumonia (ambulatory and hospitalised) in children less than 1 year was recently reported 
as between 0.20-0.27 episodes per child year6. 
Diagnostic imaging in pneumonia 
Though the incidence of pneumonia remains high, effective treatment is available once the diagnosis is made. 
Clinical signs and symptoms are a sensitive way to diagnosis pneumonia, but has limited specificity for 
distinguishing bacterial from other forms of pneumonia7,8. Nonetheless, international guidelines rely on 
clinical features alone to diagnose and treat cases where mild, uncomplicated community-acquired 
pneumonia (CAP) or viral aetiology is clinically suspected9–11. Such empiric treatment is not ideal, as it can 
lead to antibiotic overuse and drive antibiotic resistance.  Additional diagnostic tools are required to detect 
those with a high probability of bacterial pneumonia who are likely to benefit from further intervention such 
as antibiotics. Adding CXR imaging is widely available may improve specificity. CXR can also be valuable to 
establish alternative diagnoses, identify complications and monitor response to therapy. A major drawback 
of CXR, however, is ionizing radiation exposure and the associated theoretical risk of carcinogenesis which, 
despite limited supporting evidence12, remains of particular concern in children. Other limitations of CXR 
include high inter-observer variation13–16 and the cost, specialized expertise and regulatory requirements of 
a radiology service, which limits access, especially in low resource settings. Even with all these factors aside, 
studies have failed to demonstrate a significant clinical benefit from routine CXR use in uncomplicated CAP17, 
hence the recommendations by guidelines.  The regulatory requirements, expertise and cost of operating a 
radiology service further limits its availability in low-resource settings. Other modalities used less frequently 
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for childhood pneumonia include computed tomography (CT) and magnetic resonance imaging (MRI)18. CT 
can be considered the ‘gold standard’ for pneumonia imaging, but is not commonly used in uncomplicated 
CAP in children, primarily due to the much higher radiation doses used19. MRI, on the other hand, is radiation 
free, but may require sedation in young children, which also reserves its use for selected scenarios.20 The 
prohibitively high cost of both CT and MRI and need for specialised operators and paediatric radiologists 
further limits its availability to well-resourced, in-hospital settings. 
Ultrasound can also discriminate healthy from unhealthy lungs and detect different types of lung and chest 
pathology, including signs of pneumonia21. Ultrasound has the advantage of being completely radiation free 
which makes it attractive from a safety perspective for use in paediatrics, especially in situations where 
repeated imaging is required. Increasingly mobile ultrasound machines have also sparked growing interest in 
its use outside the radiology department by non-radiologists clinicians22,23 referred to as point-of-care, 
clinician-performed or bedside ultrasound and telemedicine has enabled images to be sent remotely for 
interpretation of images by skilled radiologists24. Point-of-care ultrasound is already a regular part of 
everyday practice in specialities such as emergency medicine and critical care, with some reports even 
suggesting it will eventually become as common a diagnostic aid as the stethoscope22. These factors, 
combined with relatively lower cost compared to CXR makes ultrasound a potentially safer and more 
accessible diagnostic tool for pneumonia in children. However, the starting point to understanding the role 
of LUS relative to other imaging modalities is to know its relative accuracy. The objective of this paper was to 
perform a structured literature review and meta-analysis to assess the diagnostic accuracy of LUS compared 
to CXR. 
LUNG ULTRASOUND 
Equipment and technique 
A variety of commercially available ultrasound systems have been used in diagnostic accuracy studies. 
Comparative studies to determine an optimal combination of machine specifications, settings and scanning 
protocols have not been done and are probably unnecessary. Rather, users should understand how to 
optimise equipment settings and probe selection to the size and individual characteristics of each patients. 
High frequency (5-15MHz), small linear or micro-convex probes are usually appropriate for visualisation of 
the pleura and sub-pleural anatomy through the narrow intercostal spaces of young children.  A standardized, 
systematic scanning protocol, similar to that described by Copetti et al should be used to ensure scanning of 
the entire chest25. One study found that addition of a trans-abdominal approach was able to detect 
pneumonia in the lung bases which would otherwise have been missed and should be a standard part of any 
scanning protocols8. Patients can by scanned in laying or sitting position26. Pleural effusions tend to collect in 
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dependent areas and need to be specifically looked for to avoid missing small collections. Efforts should be 
made to keep the child comfortable and calm, as excessive movement from an uncooperative child can affect 
scans quality. 
Sonographic findings 
Several sonographic findings have been described which can be used to distinguished those with and without 
pneumonia. The most prevalent pneumonia-related abnormal findings are sub-pleural consolidation, 
multiple or confluent B-lines (interstitial disease picture), which can be localised or diffuse, pleural line 
irregularities and pleural effusion27,28.  Two studies which compared LUS findings in children with clinical signs 
of ALRI to healthy controls found that sub-pleural consolidation, interstitial disease picture, pleural line 
irregularities or pleural effusion were all significantly associated with infection28,29. There were also a positive 
correlation between clinical and laboratory markers of disease severity and frequency of abnormal 
sonographic findings29,30. Further, follow-up studies of pneumonia cases have reported resolution of these 
findings following the illness29,31,32. In contrast, one study comparing pneumonia cases to controls with upper 
respiratory symptoms only, showed a significant overlap in sonographic findings of both interstitial picture 
and consolidation, although the clinical case definition used for pneumonia in this study may have 
contributed to some misclassification of cases and controls33. Few, isolated B-lines were equally present in 
both mild disease cases and healthy controls and is not considered an abnormal finding29. 
Meta-analysis of test accuracy 
Meta-analytic methodology was used to pool accuracy results and assess methodological factors which may 
influence accuracy. Using the specified eligibility criteria 22 studies totalling 2756 participants were included. 
Characteristics of included studies are summarised in Table 1. The reference standard used could broadly be 
classified into two groups: those using CXR findings alone (16 studies)34–48 and those using an ex post final 
diagnosis of pneumonia (6 studies)25,27,49–52. Of the latter, 3 studies27,49,52 used purely clinical, standardised 
criteria (British Thoracic Society guidelines), while the remaining 3 studies25,50,51 used all available evidence 
(laboratory, CXR results and response to treatment) in a non-standardized way (expert opinion). Diagnostic 
endpoint definitions also varied considerably, both for the index test and reference standard. For example, 
sonographic consolidation considered the definitive feature of pneumonia on LUS, was limited to lesions 
containing air-bronchograms in 9 studies30,39,41,45,46,49,52–54 presumably to distinguish alveolar consolidation 
from collapse, while the rest of the studies did not make this distinction. Also, very small sonographic 
consolidations (diameter less than 1cm or 1 intercostal space) were excluded (or at least analysed separately) 
in only 4 studies 46,48,52,54. This cut-off was chosen because lesions smaller than 1cm is typically not visible on 
CXR though frequently detected on LUS39,  which will lead to decreased specificity of LUS if CXR is considered 
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the reference standard, despite LUS actually detecting lesion missed by CXR. Similarly, only 6 studies 
considered sonographic interstitial disease pattern (without consolidation) diagnostic of 
pneumonia27,32,41,49,51,55. In contrast, interstitial pattern on CXR was considered diagnostic of pneumonia in 13 
studies27,30,55–57,32,34,36,41,51–54. The WHO standardized interpretation methodology for CXR reporting, aimed at 
minimising inter-observer variation and standardized interpretation of findings, was applied in only 6 
studies39,41,45,55,56,58, while the rest either used non-standardized CXR reporting or did not state how CXR 
results were classified.  
Overall pooled sensitivity of LUS was 95% (95% confidence interval (CI): 92%-97%) and pooled specificity was 
88% (95% CI: 66%-96%) (Figure 1), which is in line with four similar, previously published meta-analyses59–62.  
However, meaningful comparison between LUS and CXR using these results are problematic as the majority 
of these studies used CXR as reference standard, which by default assumes 100% accuracy for CXR. The 
problem with this is two-fold: firstly, it is well established that the true accuracy of CXR is in fact not 100%, 
and secondly, the problem with using an imperfect reference standard is that it will negatively bias accuracy 
of the index test in cases with LUS-positive-CXR-negative discordant results, even though the true disease 
status in these cases are unclear and LUS may in fact be detecting cases missed by CXR.   Another problem 
with these results is that some of the studies which used an ex post diagnosis of pneumonia as reference 
standard incorporated CXR, but not LUS findings into the final diagnosis, which are likely to bias accuracy 
results in favour of CXR.  
As an alternative approach, concordance (agreement) between LUS and CXR was calculated for this subgroup 
of 16 studies which used CXR alone as reference standard (Table 2). This approach avoids the problems of an 
imperfect reference standard (CXR), while still allowing direct comparison between CXR and LUS. Pooled 
overall observed agreement (OOA) was 0.88 (95% CI: 0.87-0.89), with proportion positive agreement (PPA) 
= 0.90 (95% CI: 0.88-0.91), proportion negative agreement (PNA) = 0.86 (95% CI: 0.84-0.88) and Kappa=0.76 
(95% CI: 0.73-0.78). In contrast, the 6 studies (496 participants) which calculated accuracy of both LUS (as 
index test) and CXR (as comparator test) against a common reference standard of ex post diagnosis of 
pneumonia47–49,56,57 allowed for a different comparison.  Pooled results of this subset of studies (Figure 2) 
found sensitivity (Se) was higher for LUS (Se=98%, 95% CI: 95%-99%) than for CXR (Se=92%, 95% CI: 86%-
97%). Pooled specificity (Sp) for LUS was also higher (Sp=95%, 95% CI: 89%-99%) than for CXR (Sp=90%, 95% 
CI: 80%-97%). Although these differences were not found to be statistically significant, as is evident from the 
overlapping confidence intervals, this may be due to small sample size limitations (496 participants) rather 
than the lack of a true difference. 
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Methodological heterogeneity and subgroup analysis 
Overall pooled results ignore the methodological differences between studies and the effect it may have on 
test accuracy. Exploratory subgroup (stratified) analysis was therefore performed to investigate the effect of 
several clinically important variable (additionally to the difference in reference standards already considered) 
on sensitivity and specificity of LUS. These included sonographic and radiographic endpoint definitions, 
different definitions of sonographic consolidation, level of sonographer expertise and number of CXR views 
used (Table 3). When considering different test endpoint definitions, specificity was notably higher when CXR 
positivity was defined as consolidation alone as compared to any abnormality (Sp: 91% vs 82%), while 
sensitivity was equal between subgroups (Se: 95% vs 95%). Both sensitivity and specificity were better when 
LUS positivity was defined as any abnormality as compared to sonographic consolidation alone (Se: 97% vs 
94%; Sp: 91% vs 84%). With respect to different definitions for sonographic consolidation, a broad definition 
(any consolidation) yielded higher specificity compared to a restricted definition (excluding lesions <1cm 
and/or lesions without bronchograms) (Sp: 90% vs 85%) while sensitivity was not notably affected (Se: 96% 
vs 95%). When different levels of sonographer expertise were compared, expert operators yielded slightly 
higher sensitivity compared to non-experts (Se: 96% vs 92%), though sensitivity was excellent for both 
groups, while not showing any difference in specificity (Sp: 89% vs 89%). Sensitivity was not affected by the 
number of CXR views used (Se: 95% vs 95%), though specificity was higher when no lateral view was used. 
Though none of the reported subgroup differences in this exploratory analysis were statistically significant, 
as can be seen from the overlapping confidence intervals in Table 3, this should be viewed in the light of the 
sparsity of data (22 studies) rather than considering it a true lack of effect. 
Considerations other than accuracy 
Two studies which assessed point-of-care LUS use in the emergency department as a diagnostic tool for 
pneumonia in children reported significant cost and time savings when compared to CXR63,64.  However, while 
these results reflect time savings for patients (time to discharge or definitive care), it is important to consider 
that for clinicians performing point-of-care scans, the procedure adds additional time spent examining 
patients to their workload. The typical duration of LUS has been reported as ranging from 5-20 
minutes46,48,49,55,65. One of these studies, a pragmatic randomized clinical trial, also showed that the 
introduction of LUS decreased clinicians reliance on CXR, effectively decreasing use of CXR. The same study 
also investigated the impact of LUS on antibiotic prescription and found slightly increased antibiotic use in 
the investigational arm (LUS with optional CXR) compared to the control arm (CXR and LUS performed), but 
the clinical impact of this have not yet been robustly evaluated. In addition to diagnostic use, follow-up 
studies have also shown the usefulness of LUS to monitor disease resolution and response to treatment while 
avoiding repeated radiation exposure29,31,32.  LUS is also able to detect complications including pleural 
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effusion, pneumothorax, atelectasis, lung necrosis and abscess66. In fact, LUS had been shown to be as 
sensitive as CT to detect effusion and superior to CT for characterization of effusions67. 
Limitations of LUS 
There are also important limitations to the suitability of ultrasound for imaging of the lungs. Firstly, air in 
healthy lung tissue does not reflect ultrasound waves which makes direct visualisation of air-filled lung 
parenchyma and deep lung structures with overlying air by ultrasound impossible. Secondly, much of the 
lung surface is covered by calcified bone of the thoracic cage, which is impenetrable to ultrasound. These 
limitations mean ultrasound may potentially miss pneumonia not extending to the pleura or in areas covered 
by bone, such as the sub-scapular regions31,32,56,68. Another potentially limiting factor is the training 
requirements for clinicians with minimal prior ultrasound experience to achieve reliable results, as ultrasound 
findings are known to be operator dependent. However, evidence suggest that this can be achieved by 
relatively little training. In a recent meta-analysis59 which compared results of expert and non-expert LUS 
practitioners, accuracy was found to be only slightly higher when scans were performed by experts compared 
to non-experts, while training in the included studies ranged between 1hr to 1 week, suggesting that LUS is 
a relatively simple skill to learn, but additional training is required nonetheless33,53. These results were echoed 
by the findings of the subgroup analysis of this review (Table 3). Several studies also found inter-rater 
agreement of LUS to be substantial to high (Kappa = 0.55-0.93)52,53,65,69,70. 
DISCUSSION 
Pneumonia remains a global health priority in children. Clinical signs, including auscultation with a 
stethoscope, have limited diagnostic accuracy and imaging tests continue to have an important role in the 
diagnosis and management of pneumonia. CXR imaging is the current standard of care, but is not 
recommended for routine use in children due to concerns about radiation exposure and is frequently 
unavailable in settings where the burden of childhood pneumonia is the highest due to resource constraints. 
CT and MRI are also viewed as unsuitable for routine use for pneumonia in children due to limitations such 
as cost and perceived radiation risk.  
In this review we used paired CXR and LUS data from 22 studies totalling 2756 participants to compare 
diagnostic accuracy of LUS using CXR as reference standard.  Pooled results from all studies, ignoring 
methodological heterogeneity, found that LUS had sensitivity of 95% (95% CI: 92%-97%) and specificity of 
87% (69%-97%). However, as CXR cannot be considered a true gold standard and due to the variation in 
diagnostic definitions used and other methodological heterogeneity, the validity of these overall pooled 
results is questionable and make meaningful comparison between LUS and CXR problematic. In an alternative 
28 
representation of the data, results from 16 studies all using CXR as reference standard found a high level of 
agreement between LUS and CXR, with the overall observed agreement = 0.88 (95% CI: 0.87-0.89), positive 
agreement = 0.90 (95% CI: 0.88-0.91), negative agreement = 0.86 (95% CI: 0.84-0.88) and overall inter-test 
agreement of Kappa=0.76 (95% CI: 0.73-0.78). In this subgroup of studies reporting sensitivity and specificity 
would not be meaningful, as it by default assume 100% accuracy for CXR as reference standard, which is not 
the case. Hence, concordance may be a better way to compare performance of LUS and CXR in this scenario. 
In a separate subgroup of 6 studies which separately compared both LUS and CXR respectively against a 
common reference standard (final ex post diagnosis of pneumonia), both sensitivity and specificity of LUS 
was found to be higher than CXR [Se: 98% (95% CI: 95%-99%) vs 92% (95% CI: 86%-97%); Sp: 95% (95% CI: 
89%-99%) vs 90% (95% CI: 80%-97%). These results suggest that LUS may in fact be more sensitive and 
specific than CXR and studies using CXR as reference standard may therefore be underestimating accuracy 
of LUS.  
This review also highlighted the significant methodological heterogeneity found across studies and 
investigated how several of these factors may affect accuracy of LUS. Results from exploratory subgroup 
analyses suggest that the reference standard used, imaging endpoint definitions (both radiographic and 
sonographic), definitions of specific sonographic findings, level of sonographic expertise and number of CXR 
views may all affect accuracy to a varying degree. However, sensitivity of LUS generally remains high (≥92%) 
across all subgroups, though specificity appears to be more affected by methodological variation with point 
estimates dropping as low as 77% in certain subgroups. 
This overall high sensitivity and moderate to high specificity of LUS, as well as the high level of agreement 
between CXR and LUS, and the fact that the reasons for non-concordance are well-understood may be 
sufficient to make a rational argument for interchangeable rather than just complementary use of these two 
imaging modalities, while keeping in mind the fact that neither modality should be used in isolation for 
decision making without considering the broader clinical picture. 
Areas requiring further research include the development and validation of standardized LUS interpretation 
methodology similar to the WHO standardized interpretation of CXR. Further research is also needed to 
clarify the defining features of clinically significant consolidation, as well as the clinical significance of 
interstitial disease picture without consolidation as these appear to be major points of contention. 
Additionally, further studies using CT as reference standard, where clinically and ethically justifiable, would 
be the ideal to investigate LUS accuracy. Lastly, pragmatic diagnostic randomised trials comparing the impact 
LUS and CXR on clinical outcomes, in a scenario where this is ethically justifiable, would be the ideal to inform 
policy on the potential substitution of CXR with LUS for diagnosis of pneumonia. 
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Table 1: Summary of important study characteristics and characteristics of the index test(s) and reference standard used of included studies. 
Study Study design and population Index test (LUS) Comparator (CXR) Reference standard 
Author, year 
published 
Data 
collection 
Sampling 
method 
Sample 
size  
(M : F) 
Mean 
age 
(months) 
Clinical 
setting 
Main eligibility criteria 
Operator 
expertise 
Positive endpoint definition: 
Views 
used 
Positive endpoint 
definition: Broncho- 
grams 
required  
Conso-
lidation 
size 
Interstitial 
pattern 
included 
Copetti, 2008 Prospective Convenience 79 (NR) 61 ED Clinical suspicion of 
pneumonia 
Expert Unclear Any size Unclear PA/AP only Unclear Ex post diagnosis of pneumonia (not using 
standardized guidelines) 
Caiulo, 2013 Prospective Convenience 102 (53:49) 60 Paediatric 
ward 
Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Expert No Any size Yes PA/AP only Alveolar and/or 
interstitial pattern 
Ex post diagnosis of pneumonia (using BTS 
guidelines) 
Seif el Dien, 2013 Prospective Consecutive 75 (36:39) 0.3 NICU Neonates hospitalised with 
clinical suspicion of 
pneumonia (onset after 48hrs 
of life) 
Expert No Any size No PA/AP only Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Shah, 2013 Prospective Convenience 200 (112:88) 36 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Mixed Yes Any size No PA/AP & Lat Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Esposito, 2014 Prospective Consecutive 103 (56:47) 67 PICU Hospitalised with clinically 
diagnosed pneumonia  
Novice Yes Any size Yes PA/AP & Lat Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Reali, 2014 Prospective Consecutive 107 (61:46) 48 Paediatric 
ward 
Clinical suspicion of 
pneumonia 
Expert Yes Any size Yes PA/AP only Unclear Ex post diagnosis of pneumonia (using BTS 
guidelines) 
Iorio, 2015 Retrospective Consecutive 52 (NR) 42 Paediatric 
ward 
Hospitalised with 
mild/uncomplicated 
respiratory sign & symptoms 
Expert No Any size No PA/AP only Alveolar pattern only Ex post diagnosis of pneumonia (not using 
standardized guidelines) 
Urbankowska, 
2015 
Prospective Consecutive 106 (39:67) 53 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Expert No Any size No Unclear Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Guerra, 2016 Prospective Consecutive 222 
(108:114) 
59 ED Clinical suspicion of 
pneumonia: moderate to 
severe respiratory distress + 
high fever 
Intermediate Yes Any size No Mixed Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Ianniello, 2016 Retrospective Consecutive 84 (44:40) NR ED Clinical suspicion of 
pneumonia 
Unclear No Any size Yes PA/AP & Lat Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Samson, 2016 Prospective Consecutive 200 (116:84) 30 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Mixed Yes Any size No PA/AP only Alveolar pattern only Radiographic pneumonia as defined by CXR 
endpoint 
Zhan, 2016 Prospective Convenience 82 * (47:35) 18 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Novice Yes >1cm No PA/AP only Unclear Radiographic pneumonia as defined by CXR 
endpoint 
Boursiani, 2017 Prospective Consecutive 69 (27:42) 54 ED Clinical suspicion of 
pneumonia and had CXR at 
Expert No Any size Yes PA/AP only Alveolar and/or 
interstitial pattern 
Ex post diagnosis of pneumonia (not using 
standardized guidelines) 
35 
discretion of attending 
physician 
Claes, 2017 Prospective Consecutive 143 (77:66) 31 Radiology 
department 
Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Expert No Any size No PA/AP only Alveolar pattern only Radiographic pneumonia as defined by CXR 
endpoint 
Ellington, 2017 Prospective Consecutive 421 (NR) NR Clinic, ED & 
ward 
Clinically and radiologically 
defined pneumonia and 
healthy controls 
Intermediate No >1 ICS No PA/AP only Alveolar pattern only Radiographic pneumonia as defined by CXR 
endpoint 
Man, 2017 Retrospective Consecutive 81 (42:39) 78 Paediatric 
ward 
Hospitalised with clinical 
suspicion of pneumonia 
Expert No Any size No PA/AP only Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint* 
Yadav, 2017 Prospective Convenience 118 (65:53) 26 Paediatric 
ward 
Hospitalised with clinically 
diagnosed pneumonia  
Expert No Any size Yes Unclear Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Yilmaz, 2017 Prospective Convenience 149 (79:70) 16 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physcian 
Expert Unclear Any size Unclear PA/AP only Unclear Radiographic pneumonia as defined by CXR 
endpoint 
Biagi, 2018 Prospective Consecutive 87 (43:44) 6 Paediatric 
ward 
Clinical diagnosed bronchiolitis 
and clinical suspicion of 
concomitant pneumonia 
Intermediate Yes Any size No PA/AP only Alveolar and/or 
interstitial pattern 
Ex post diagnosis of pneumonia (using BTS 
guidelines) 
Iorio, 2018 Retrospective Consecutive 47 (27:20) 48 Paediatric 
ward 
Hospitalised with diagnosis of 
pneumonia  
Expert Yes Any size No PA/AP only Alveolar pattern only Radiographic pneumonia as defined by CXR 
endpoint 
Lissaman, 2018 Prospective Consecutive 97 (50:47) 29 ED Clinical suspicion of 
pneumonia and had CXR at 
discretion of attending 
physician 
Novice Yes Any size No PA/AP only Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint 
Omran, 2018 Prospective Convenience 50 (30:20) 6 Paediatric 
ward 
Clinical defined pneumonia 
(BTS guidelines) and had CXR 
at discretion of attending 
physician 
Expert No Any size No PA/AP only Alveolar and/or 
interstitial pattern 
Radiographic pneumonia as defined by CXR 
endpoint**  
LUS = lung ultrasound, CXR = chest X-ray, NR = not reported, M = male, F = female, ED = Emergency Department, NICU = Neonatal Intensive Care Unit, PA = posterior-anterior, AP = anterior-posterior, Lat = lateral, BTS = British Thoracic Society, ICS = intercostal space 
* LUS was also compared to clinical pneumonia, but CXR was not compared to the clinical reference standard, so no comparison was possible. 
** Comparison to clinical pneumonia was also reported, but due to unclear methodology these results were not includable.
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Table 2: Summary of studies using CXR alone as reference standard showing both measures of accuracy and 
agreement.  
Study 
Sample 
size 
TP FP FN TN Se Sp OOA PPA PNA Kappa 
Seif el Dien, 2013 75 64 0 4 7 0.94 1.00 0.95 0.97 0.78 0.75 
Shah,2013 200 31 18 5 146 0.86 0.89 0.89 0.73 0.93 0.66 
Esposito, 2014 103 47 3 1 52 0.98 0.95 0.96 0.96 0.96 0.92 
Urbankowska, 2015 106 71 0 5 30 0.93 1.00 0.95 0.09 0.92 0.89 
Guerra, 2016 222 190 17 7 8 0.96 0.32 0.89 0.94 0.40 0.34 
Ianniello, 2016 84 46 13 1 24 0.98 0.65 0.83 0.87 0.77 0.65 
Samson, 2016 200 74 6 11 109 0.87 0.95 0.92 0.90 0.93 0.82 
Zhan, 2016 164 33 7 49 75 0.40 0.91 0.66 0.54 0.73 0.32 
Claes, 2017 143 44 8 1 90 0.98 0.92 0.94 0.91 0.95 0.86 
Ellington, 2017 421 169 0 22 230 0.88 1.00 0.95 0.94 0.95 0.89 
Man, 2017 81 57 5 15 4 0.79 0.44 0.75 0.85 0.29 0.16 
Yadav, 2017 118 99 6 2 11 0.98 0.65 0.93 0.96 0.73 0.70 
Yilmaz, 2017 149 127 15 5 2 0.96 0.12 0.87 0.93 0.17 0.11 
Iorio, 2018 47 38 9 0 0 1.00 0.00 0.81 0.89 0.00 0.00 
Lissaman, 2018 97 40 17 4 36 0.91 0.68 0.78 0.79 0.77 0.57 
Omran, 2018 50 36 13 1 0 0.97 0.00 0.72 0.84 0.00 -0.04
Pooled value 
(95% CI) 
2260 1166 137 133 824 
0.89  
(0.88-0.91) 
0.86  
(0.84-0.88) 
0.88 
 (0.87-0.89) 
0.90 
 (0.88-0.91) 
0.86 
 (0.84-0.88) 
0.76 
 (0.73-0.78) 
TP = True positives, FP = False positives, FN = False negatives, TN = True negatives, Se = Sensitivity, Sp = Specificity, OOA = Overall observed agreement, PPA = Proportion positive agreement, PNA = Proportion negative agreement, Kappa = Cohen’s 
kappa-coefficient 
Table 3: Comparison of sensitivity and specificity values for subgroups (stratified analysis).  
Study characteristics with subgroup 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
CXR endpoint definition 
Consolidation alone 95% (84%-99%) 91% (21%-100%) 
Any abnormality 95% (92%-97%) 82% (54%-95%) 
Sonographic endpoint definition 
Consolidation alone 94% (89%-97%) 84% (48%-97%) 
Any abnormality 97% (94%-98%) 91% (72%-97%) 
Sonographic consolidation definition 
Broad (any consolidation) 96% (93%-98%) 90% (49%-99%) 
Restricted (excluding lesions <1cm or without bronchograms) 93% (84%-95%) 86% (57%-97%) 
Sonographer expertise 
Expert 96% (93%-98%) 89% (39%-99%) 
Non-expert 92% (82%-97%) 89% (71%-96%) 
CXR views 
PA & Lat 95% (91%-98%) 77% (46%-93%) 
PA only 95% (91%-98%) 91% (62%-98%) 
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Figure 1: Forest plot showing LUS sensitivity and specificity for all included studies and overall pooled results. 
38 
Figure 2: Forest plot of 6 studies comparing sensitivity and specificity of both LUS (as index test) and CXR (as comparator test) against a common reference standard 
(ex post diagnosis of pneumonia). 
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Abstract 
Introduction: Lung ultrasound (LUS) is radiation-free and cheaper than and chest X-ray (CXR). The objective 
of this study was to investigate the diagnostic performance of LUS compared to CXR for pneumonia in 
children in a resource-constrained, African setting. 
Methods: Children enrolled in the Drakenstein Child Health Study who presented with clinically defined 
pneumonia and had a CXR performed by the attending physician also had a LUS performed by a study doctor. 
Each modality was reported by two readers, using standardised methodology. Agreement between 
modalities, accuracy (sensitivity and specificity) of LUS and inter-rater agreement were assessed. Both 
consolidation and any abnormality (consolidation or interstitial picture) were considered as pneumonia 
endpoints.   
Results: In 102 children (median age: 7.2 months; 56% male; 70% hospitalised), prevalence was 37% vs 39% 
for consolidation and 52% vs 75% for any abnormality on LUS and CXR respectively. Agreement was poor and 
not significantly higher than expected by chance, neither for consolidation (observed agreement (OA) 61%, 
Kappa=0.17, 95% confidence interval: -0.02-0.36) nor for any abnormality (OA=55%, Kappa=0.08, -0.09-0.29). 
Using CXR as reference standard, sensitivity (Se) of LUS was low, both for consolidation (Se=48%, 32%-0.64%) 
and any abnormality (Se=55%, 43%-66%), while specificity (Sp) was moderate for consolidation (Sp=69%, 
56%-80%), but lower for any abnormality (Sp=56%, 35%-76%). Inter-rater agreement of LUS was substantial 
(Kappa=0.60, 0.47-0.74) and significantly higher than CXR (Kappa=0.25, 0.13-0.35). 
Conclusion: Accuracy of LUS in non-ideal conditions may be considerably lower than suggested by recently 
published meta-analyses, but LUS has significantly higher inter-observer agreement than CXR. 
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Introduction 
Pneumonia forms part of a spectrum of lower respiratory tract infections (LRTI). Despite a steady decline in 
mortality in recent decades, pneumonia remains the leading cause of death in children, accounting for over 
700000 child deaths each year. Pneumonia is one of the most common reasons for healthcare visits in 
children with over 100 million episodes estimated to occur globally each year1,2. Over 90% of these deaths 
occur in low and middle income countries2. 
One modifiable factor which can potentially impact pneumonia outcomes is early and correct diagnosis. 
Diagnostic algorithms based on clinical features alone, as recommend by international evidence-based 
guidelines in mild disease cases3–5, lacks specificity for bacterial pneumonia6,7. This may lead to antibiotic 
overuse and resistance. Addition of chest X-ray (CXR) imaging can improve specificity, but there are 
drawbacks such as radiation exposure, variability when interpreting results8–10 and cost, specialized expertise 
and regulatory requirements of a radiology service. Even with all these factors aside, studies have failed to 
demonstrate a clear clinical benefit from routine CXR use in cases where mild, uncomplicated community-
acquired pneumonia or viral aetiology is suspected11, hence current guidelines reserve CXR for moderate to 
severe disease and hospitalized cases, even in well-resourced settings.  Despite these limitations CXR remains 
the most widely used imaging modality for in children with suspected pneumonia, as alternatives such as 
computed tomography (CT) and magnetic resonance imaging (MRI) are perceived as having an unacceptable 
safety and cost profile. 
The ideal diagnostic test for pneumonia should be safe, accurate, cheap, quick and simple to perform. Lung 
ultrasound (LUS) is a promising imaging modality which uses no radiation, is less costly than CXR and can 
improve the time to results12 when used as a point-of-care tool by clinicians outside the radiology 
department. A number of published meta-analyses also reported high accuracy of LUS for the detection of 
pneumonia in children13–17. These characteristics make LUS an ideal option as a low risk, low cost screening 
test aimed at improving diagnosis and targeting treatment for paediatric pneumonia. Nonetheless, uptake 
of LUS in clinical practice is slow and several questions remain regarding real-world performance and 
requirements for achieving optimal results. The aim of this study was to evaluate the diagnostic performance 
of LUS compared to CXR in children presenting with clinically defined pneumonia in a low-resource, African 
setting and to identify factors which may be important for achieving optimal results. 
Methods 
The Drakenstein Child Health Study (DCHS) is a large, multi-year, population-based birth cohort study 
investigating the early life determinants of child health in Africa18, taking place in Paarl,  South Africa, a peri-
urban town approximately 50km from Cape Town. Children enrolled in the DCHS who presented to the 
emergency department of the local public hospital with acute respiratory symptoms and signs matching the 
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World Health Organisation (WHO) clinical case definition for childhood pneumonia4 and who received a CXR 
during clinical care, based on the discretion of the attending clinician, were identified and a LUS was 
performed as part of the study protocol.  Cases were consecutively enrolled, and data was prospectively 
collected between August 2014 and December 2015. All scans were performed by the same study clinician, 
a general practitioner with minimal prior ultrasound experience, but who had undergone focused LUS 
training consisting of a theoretical training session with an experienced paediatric radiologist, followed by a 
number of practice scans which were reviewed with the radiologist. LUS was usually performed within 24 
hours, but up to 72 hours from time of CXR. The sonographer was blinded to CXR findings at the time of 
performing the scan, but the indication for performing the scan was known. Scans were performed using a 
commercially available ultrasound machine (Mindray DP10, Mindray Bio-Medical Electronics Co. Ltd) with a 
micro-convex probe. Default machine settings (Frequency: 7.5MHz, Gain: 35, Depth: 4cm) were adjusted 
according to individual patient characteristics for optimal visualization. A standardized, systematic scanning 
protocol was used by dividing each hemi-thorax into four quadrants: anterior and posterior halves divided 
by the mid-axillary line, sub-divided into upper and lower quadrants at the level of the nipple line (Figure 1). 
Each quadrant was scanned diagonally by moving the probe from one intercostal space to the next while 
keeping the probe parallel to the ribs and a 5-10 second video clip was recorded of each quadrant and stored. 
Participants were scanned in sitting or lying position. Dependent areas were checked for pleural fluid 
collections. Considerable effort was made to keep children comfortable and calm during scans, often 
scanning children on the mother’s lap while breastfeeding, as excessive movement from an uncooperative 
child negatively affected the performance and interpretability of scans. Each scan consisting of eight video 
clips was later reported independently by two reporters: the study clinician (general practitioner) who 
performed the scans and a paediatric radiologist, both blinded to CXR findings at the time of reporting the 
LUS. LUS findings were classified as typical of pneumonia (consolidation present), interstitial syndrome (focal 
or generalized pathological B-lines, but no consolidation) or normal. Definition details are summarised in 
Table 1 with Figure 2 showing characteristic examples of diagnostic categories. 
A posterior-anterior (PA) CXR was done on all children and a lateral view was also attained in some at 
discretion of the attending clinicians. CXR images were reported independently by two experienced 
paediatricians blinded to LUS results, but aware of the indication for the CXR. CXR results were classified 
using the WHO standardized interpretation methodology for pneumonia in children.19 For a final result, 
disagreement between LUS readers was resolved pragmatically by accepting the read of the paediatric 
radiologist, while CXR disagreement was adjudicated by using a third independent reader and accepting the 
result on which the majority readers agreed. CXR findings in keeping with pneumonia (radiographic 
pneumonia) were considered the reference standard for calculating accuracy. Radiographic pneumonia was 
defined in terms of WHO radiographic reporting categories (Table 1) and accuracy was calculated separately 
considering both consolidation and any abnormality (other infiltrates included) as diagnostic endpoints for 
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pneumonia. Despite recognition of the limitations of CXR as reference standard, this choice allows for 
comparison of results with other studies using similar methodology.  
Data collection was performed using REDCAP electronic data capturing platform (Vanderbilt University, 
Nashville, Tennessee, USA) and statistical analysis was performed using STATA version 15 statistical software 
package (StataCorp Inc, College Station, Texas, USA). Categorical variables were expressed as simple 
frequencies (n), percentages (%) or proportions, while continuous variables were summarised using median 
and interquartile range (IQR). Sensitivity (Se) and specificity (Sp) were calculated as measures of test accuracy 
using 2x2 tables classifying LUS and CXR as positive or negative for specified findings. As CXR is considered 
an imperfect reference standard, the same 2x2 tables were used to calculate concordance between LUS and 
CXR (inter-test agreement) as an alternative way of comparing LUS and CXR findings. As proposed by Cicchetti 
et al20 multiple measures of agreement were reported concurrently rather than a single omnibus index: 
overall observed agreement (OOA) = (LUS&CXR positive + LUS&CXR negative)/total cases; proportion positive 
agreement (PPA) = (2*LUS&CXR positive)/(total LUS positive + total CXR positive); proportion negative 
agreement (PNA) = (2*LUS&CXR negative)/(total LUS negative + total CXR negative) and Cohen’s Kappa. 95% 
confidence intervals (95% CI) were calculated for statistical inference.  There were no equivocal test results 
in our data.  
The study was approved by the Human Research Ethics Committee of the University of Cape Town and 
written consent was given by a parent or legal guardian of all children at enrolment in the study and again 
annually. Assent was not sought, as all children were below 5 years of age at the time of data collection. 
Results 
Between August 2014 to December 2015, 529 clinically defined pneumonia cases were observed in the DCHS 
cohort, of which 134 (25%) had a CXR done based on the discretion of the treating clinicians. Cases of 
neonatal respiratory distress with onset directly following delivery were excluded (n=11), as these were 
unlikely to represent true pneumonia. Of the remaining 123 cases with a CXR, 102 also had LUS results 
available (Figure 3). Demographic, clinical and imaging characteristics of the 102 analysed cases are 
summarised in Table 2. The median age was 7.2 (IQR: 15.7) months, 56% (n=57) of participants were male 
and 70% (n=71) required inpatient hospitalisation while the rest received outpatient care only. Hypoxia 
(oxygen saturation <92%) were document in 25% (n=25) and 31% (n=32) received supplemental oxygen of 
which 6 also required non-invasive ventilatory support. No cases required invasive ventilation and no 
fatalities occurred. Prevalence of HIV exposure was 23% (n=23), but there were no HIV infected cases. The 
majority (85%, n=83) had both PA and lateral CXR views available. 
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Sonographic consolidation was present in 37% of cases compared to 39% radiographic consolidation (Table 
2). However, when comparing the presence of consolidation (Table 3), agreement between LUS and CXR was 
poor and not significantly different from what would be expected by chance (OOA = 61%, PPA=49%, 
PNA=68%, Expected agreement = 53%, Kappa = 0.17, 95% CI: -0.02-0.36). Using radiographic consolidation 
as reference criterion, the sensitivity of LUS was low (Se=0.48, 95% CI: 0.32-0.64) and specificity was 
moderate (Sp=0.69, 95% CI: 0.56-0.80). Prevalence of any abnormality (both consolidation and interstitial 
disease picture without consolidation) was higher on CXR (75%) than on LUS (52%) compared. When 
comparing any abnormality on LUS and CXR (Table 4), agreement again was poor on and not significantly 
better than what could be expected by chance (OOA=55%, PPA=65%, PNA=38%, Expected agreement=51%, 
Kappa=0.08, 95% CI: -0.09-0.29). When considering any abnormality as a positive result, instead of 
consolidation alone, sensitivity LUS improved from 48% for consolidation to 56% for any abnormality, but 
specificity decreased from 69% for consolidation to 56% for any abnormality. Ultrasound found no 
abnormality (no consolidation or interstitial picture) in almost half (48%) of cases compared to only 25% on 
CXR with the probability of both tests finding no abnormality also being low with PNA = 0.38 (0.24-0.52). No 
pleural effusions or pneumothoraxes were identified on either modality. 
Overall inter-observer agreement (IOA) of CXR (Table 5), interpreted by two experienced paediatricians, was 
poor in this study (Kappa=0.25, 95% CI: 0.13-0.35) and was statistically significantly lower than for LUS (Table 
6) interpreted by a general practitioner and a paediatric radiologist (Kappa=0.60, 95% CI: 0.47-0.74).  When
comparing different LUS findings (Table 7), IOA was substantial for consolidation (Kappa=0.69, 95% CI: 0.54-
0.83), but moderate for interstitial picture (Kappa=0.43, 95% CI: 0.24-0.61). When comparing IOA for each 
type of finding across modalities LUS had better IOA than CXR for all categories of findings, showing a 
statistically significant difference for consolidation (Kappa=0.69, 95% CI: 0.54-0.83 vs Kappa=0.32, 95% CI: 
0.14-0.51), as can be seen from the non-overlapping confidence intervals (Table 7). 
Discussion 
Pneumonia remains a global health priority in children. Diagnostic imaging has an important role to play in 
improving pneumonia outcomes. CXR remains the first line and most widely used option when imaging is 
required but has significant limitations, including availability, cost, requirement for radiologic services and 
equipment, interpretation variability, and exposure to radiation. LUS overcomes some of these limitations 
and current evidence suggests that LUS may have accuracy similar to CXR 13-17. In this study we compared the 
diagnostic performance of LUS to CXR in a real world, resource-constrained scenario: we applied LUS in a 
diverse spectrum of disease, using relatively low-end ultrasound equipment and a simplified scanning 
protocol, performed by a general practitioner with minimal prior experience and training. Contrary to the 
bulk of current literature, sensitivity and specificity of LUS in this study were low to moderate and did not 
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change considerably, whether pneumonia was defined as consolidation alone or any abnormality. Caution 
should be taken when interpreting sensitivity and specificity determined by using an imperfect reference 
standard such as CXR, as true disease status remains in question in cases when results of the index test and 
reference standard are discordant. As an alternative method of comparing test performance, this study 
reported concordance between CXR and LUS findings. Agreement between modalities was found to be only 
slightly better than what may have been expected by chance (Kappa=0.08-0.17), independent of which 
endpoint definition was used. Inter-observer agreement was statistically significantly better for LUS than for 
CXR (Kappa, 95% CI: 0.25 (0.06-0.40) vs 0.60 (0.49 - 0.74), despite CXR being interpreted by specialist clinicians 
using a standardized interpretation method, highlighting this inherent weakness of CXR. 
There were notable limitations to our study, some which may have contributed to the difference in the 
observed results as compared to other literature. Not unique to this study was the lack of a true gold 
standard, which may have negatively affected accuracy measures. Our approach to this was to report 
multiple measures of concordance also, rather than accuracy only. We postulate that one of the major factors 
contributing to lower than expected accuracy was the learning curve for the relatively inexperienced general 
practitioner who was the sole sonographer in this study. This is supported by the observation that sensitivity 
calculated for the first thirty scans done was 36% compared to 70% for the last thirty scans. A second possible 
factor is that ultrasound results were based on retrospective interpretation of eight video clips of 5-10 
seconds each. It is possible that the diagnostic yield may have been better if video clips were longer or 
reported in real time by the person performing them, taking into consideration the full scan and not just 
short video segments. We also used a simplified scanning protocol as compared to that describe by Copetti 
et al 21 which divides the chest into anterior, posterior and lateral regions, nor did we include a trans-
abdominal approach shown by Lovrenski et al 7 to increase diagnostic yield. We also did not measure the size 
of consolidations. It has been shown by several studies that consolidations smaller than 1-1.5cm is typically 
not visualized on CXR and diagnostic accuracy of LUS is improved if these are excluded when using 
radiographic consolidation as reference standard22–24. These limitations are highlighted may serve as valuable 
learning points for future studies and clinical practice. 
Conclusion 
In this study LUS for the detection of pneumonia had low sensitivity and specificity, although this was 
determined using an imprecise reference standard, as is evident from the large proportion of CXR-negative-
LUS-positive cases and the significantly lower inter-observer agreement of CXR. Considering the poor 
concordance between LUS and CXR and the well-understood limitations of each, it is appropriate to conclude 
that neither should be used as reference standard for the other and to question the validity of the reported 
accuracy measures this study and other studies using similar methodology. What is needed instead, are 
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studies comparing both CXR and LUS against a strong gold standard, ideally CT, under conditions where this 
is ethically justifiable. Perhaps, when considering where pneumonia ranks amongst causes of childhood 
mortality, the obvious limitations of CXR and the significant reduction in radiation dose achievable for chest 
CT today, it is worth asking if the justifications for NOT using CT are still as valid as previously judged? 
Otherwise we may end up substituting one inaccurate test with another and later find that there was little 
to gain. For now, we can only conclude that in a setting where no other form of imaging is available, there is 
no doubt that LUS will add value, but in the context where CXR is readily available, the role of LUS remains 
less clear. Ultimately, once the question of accuracy, first under ideal circumstance then real-world 
conditions have been adequately addressed, the role of LUS will best be clarified by randomised studies 
evaluating how LUS affects patient outcomes compared to other modalities. For clinicians who have already 
started or are planning to start using ultrasound as part of their diagnostic armamentarium, it may be worth 
keeping in mind that, as with CXR, it should not be used in isolation for decision making without considering 
the broader clinical picture. 
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Table 1: Standardized classification system used for reporting of LUS and CXR findings. 
Category Definition 
Lu
n
g 
u
lt
ra
so
u
n
d
 Typical of pneumonia Any air-space consolidation with or without air-
bronchograms. Includes associated pleural effusion. 
Interstitial syndrome Pathological B-lines (>3 B-lines in a single frame or confluent 
B-lines), but no airspace consolidation or pleural effusion.
Normal A-line pattern with lung sliding present, with or without
occasional, isolated B-lines; AND absence of
consolidation/interstitial syndrome/effusion.
C
h
e
st
 X
-r
ay
 
Primary endpoint 
pneumonia 
Dense or fluffy opacity that occupies a portion or the whole of 
a lobe or the entire lung with or without air-bronchograms; 
OR pleural effusion. 
Other infiltrates Linear and patch densities in a lacy pattern involving both 
lungs; includes minor patch infiltrates that is not sufficient to 
constitute endpoint consolidation. 
No pneumonia Absence of consolidation infiltrates or effusion 
Table 2: Demographic, clinical and imaging characteristics of study participants. 
Variable All Participants (N=102) 
Age (months) 7.2 (15.7) 
Male sex  57 (56) 
HIV exposed 23 (23) 
Clinical features 
Fever (≥38°C) 42 (41) 
Oxygen saturation (lowest) <92% 25 (25) 
Wheeze present 43 (42) 
Chest wall indrawing present 85 (83) 
Supplemental oxygen given 32 (31) 
Non-invasive ventilation given 6 (6) 
Blood results 
C-reactive protein (mg/L) 7.4 (25) 
Total white cell count (x 109/L) 12.5 (7.4)  
Disposition 
Admitted to hospital 71 (70) 
Outpatient treatment 31 (30) 
LUS findings 
Typical of pneumonia 38 (37) 
Interstitial syndrome 15 (15) 
Normal 49 (48) 
CXR findings 
Primary endpoint pneumonia 40 (39) 
Other infiltrates 37 (36) 
No pneumonia 25 (25) 
CXR views 
PA only 15 (15) 
PA and lateral 85 (85) 
Data are n (%) for categorical variables and median (IQR) for continuous variables. 
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Table 3: Comparison of consolidation on LUS and CXR, with CXR as reference standard. 
Table 4: Comparison of any abnormality (both consolidation and interstitial disease 
picture without consolidation) on LUS and CXR, with CXR as reference standard. 
LUS 
CXR Positive Negative Total 
Positive 42 35 77 
Negative 11 14 25 
Total 53 49 102 
Se (95% CI) Sp (95% CI) PPA (95% CI) PNA (95% CI) Kappa (95% CI) 
0.55 (0.43 - 0.66) 0.56 (0.35 - 0.76) 0.65 (0.55-0.74) 0.38 (0.24-0.52) 0.08 (-0.09 - 0.29) 
Se = Sensitivity; Sp = Specificity; PPA = Positive agreement; PNA = negative agreement 
Table 5: Inter-observer agreement of CXR findings between two paediatricians. 
Reader 2 
Reader 1 No pneumonia Other infiltrates Endpoint Pneumonia Total 
No pneumonia 9 10 3 22 
Other infiltrates 7 20 8 35 
Endpoint pneumonia 2 19 24 45 
Total 18 49 35 102 
Kappa (95% CI) = 0.25 (0.13 – 0.35) 
Table 6: Inter-observer agreement of LUS findings between a general practitioner and radiologist. 
Reader 2 
Reader 1 Normal Interstitial syndrome Typical of pneumonia Total 
Normal 37 2 4 43 
Interstitial syndrome 11 13 9 33 
Typical of pneumonia 1 0 25 26 
Total 49 15 38 102 
Kappa (95% CI) = 0.60 (0.47 – 0.74) 
Table 7:  Comparison of inter-observer agreement between CXR and LUS for different imaging finding 
separately and overall. 
Imaging finding CXR 
Kappa (95% CI) 
LUS 
Kappa (95% CI) 
Consolidation 0.32 0.14 - 0.51) 0.69 (0.54 - 0.83) 
Interstitial picture 0.13 (-0.06 - 0.31) 0.43 (0.24 - 0.61) 
No abnormality 0.32 (0.10 - 0.54) 0.65 (0.50 - 0.79) 
Overall 0.25 (0.06 - 0.40) 0.60 (0.49 - 0.74) 
LUS 
CXR Positive Negative Total 
Positive 19 21 40 
Negative 19 43 62 
Total 38 64 102 
Se (95% CI) Sp (95% CI) PPA (95% CI) PNA (95% CI) Kappa (95% CI) 
0.48 (0.32 - 0.64) 0.69 (0.56 - 0.80) 0.49 (0.35-0.62) 0.68 (0.59-0.77) 0.17 (-0.02 - 0.36) 
Se = Sensitivity; Sp = Specificity; PPA = Proportion positive agreement; PNA = Proportion negative agreement 
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Figure 3: Flow chart of study participants and results of imaging tests. 
529 clinically defined pneumonia cases
134 with CXR as part of clinical care
102 with CXR and LUS results
32 cases excluded
• 11 Respiratory distress other than pneumonia
• 21 No ultrasound data
77 CXR positive 
(consolidation or other infiltrates)
25 CXR negative 
(consolidation or other infiltrates)
42 LUS positive 
(consolidation or interstitial picture)
35 LUS negative 
(consolidation or interstitial picture)
11 LUS positive 
(consolidation or interstitial picture)
14 LUS negative 
(consolidation or interstitial picture)
Figure 2: Diagrammatic representation of simplified ultrasound scanning protocol. 
Figure 2: Examples of characteristic sonographic findings in pneumonia: (A) healthy lung characterized 
by a smooth pleural line with parallel running  A-lines, but no (or minimal) B-lines;  (B) interstitial 
disease picture characterized by an irregular pleural line with multiple or confluent B-lines;  (C) air-
space consolidation characterized by a sub-pleural hypoechoic lesion with loss of the over-lying pleural 
line, irregular (“shredded”) deep borders, and internal hyper-echoic punctate lesion indicating air-
bronchograms. 
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(Sub-study llnked to 401/2009) (MASTERS CANDIDATE - DR J. STADLER) 
Thank you for submitting your study to the Faculty of Health Sciences Human Research Ethics 
Committee (HREC) for review. 
It Is a pleasure to inform you that the HREC has formally approved the above-mentioned study. 
Approval Is granted for one year until the 30 August 2019. 
Please submit a progress form, using the standardised Annual Report Form If the study continues 
beyond the approval period. Please submit a Standard Closure form If the study Is completed within the 
approval period. 
(Forms can be found on our website: www.health.uct,ac.za/fhs/research/humanethics/forms) 
We acknowledge that the student: Dr ,acob Stadler will also be involved In this study. 
Please quote the HREC REF In all your correspondence. 
Please note that the ongoing ethical conduct of the study remains the responslblllty of the principal 
Investigator. 
Please note that for all studies approved by the HREC, the prlnclpal Investigator m.llll obtain appropriate 
Institutional approval, where necessary, before the research may occur. 
Yours sincerely 
PROFESSOR M &LOCKMAN 
CHAIRPERSON. FHS HUMAN RESEARCH ETHICS COMMITTEE 
Federal Wide Assurance Number: FWA00001637. 
Institutlonal Review Board (IRB) number: IRB00001938 
Signature Removed
This serves to confirm that the University of Cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Clinical Research with a new drug in patients, based on the Medical 
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), International Convention on 
Harmonisation Good Clinical Practice (ICH GCP), South African Good Clinical Practice Guidelines (DoH 
2006), based on the Association of the British Pharmaceutical Industry Guidelines (ABPI), and 
Dedaratlon of Helsinki (2013) guidellnes. 
The Human Research Ethics Committee granting this approval Is In compliance with the ICH 
Harmonised Tripartite Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) 
and FDA Code Federal Regulation Part 50, 56 and 312. 
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DRAKENSTEIN CHILD LUNG HEALTH STUDY  
CONSENT AND INFORMATION SHEET FOR MOTHERS – MAIN COHORT 
 August 2015 
CONSENT FORM AT YEAR 1 
You and your child are invited to continue to take part in a study that is being done in the Drakenstein 
sub-district, in collaboration with the Universities of Cape Town and Stellenbosch. The following 
information describes the study for the second year and you and your child’s role. Please read this 
carefully and feel free to ask any questions. 
Why is this study being done? 
Lung infections and chest problems are common in young children. This study is being done to find out 
the effect of chest infections in the early years of life on the development of lung disease in children.  The 
study will also look at a number of other factors that may affect your child’s health.  
You and your child will continue to attend occasional scheduled visits at your primary health care clinic 
and at Paarl Hospital. During these visits, we will assess the health of you and your child by using 
questionnaires and doing tests. Should your child get sick with a chest infection, then he/ she will be 
carefully investigated to try and find out the cause of this infection.  This study will help us to better 
understand why children get chest illness and may help to improve child health. 
What must I do if I agree to continue in the study? 
If you agree to continue in this study, we will follow you and your child regularly to assess his/ her health.  
We will see you and your child at Paarl hospital when your child is about 1 year of age and again at about 
2 years of age.  We will also schedule a visit at 1 year of age and at 18 months at the primary health care 
clinic.  We will ask you some questions about your child’s health, nutrition, growth and development, and 
any chest illnesses. We will do regular tests to watch these. 
At study visits in the next year, you will be asked some questions about you and your child’s health. Your 
child will be examined. Tests will be done on you and your child to assess whether there is any chest 
problem. The tests that may be done on your child are: 
1. Blood tests - these will be to test for allergies or blood problems.
2. A test of the mucus from the nose (nasopharyngeal swab) to test for infection.
3. Saliva will be collected to check for germs which may cause pneumonia
4. A skin test for tuberculosis infection.
5. A urine test for smoke exposure.
6. A stool test to check what germs are in the stool.
7. A set of developmental measures in a subset of infants.
8. At 1 year and 2 years of age a breathing test will be done while your child is sleeping, to
measure the air moving in and out of his/her lungs.
9. A skin test if your child has a rash
The tests YOU will be asked to complete are: 
1. Questionnaires about your socioeconomic status and your levels of emotional distress,
stress, life events, and drug and alcohol use.  If a mental health condition or abuse is
suspected, you will be referred to the appropriate local services.  You may also be
invited to return to undergo more thorough follow-up.  This voluntary follow-up
session will involve a clinical/psychiatric interview; and a neuropsychological
assessment that tests your memory, problem-solving skills, and your attention.
2. A questionnaire and an interview about your experiences while in the Drakenstein
Child Lung Health Study.
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We will only share your test results with primary health care staff if it indicates that you or your child 
require treatment or further follow up.   For some assessments, study staff may follow up with you and 
provide you with information on where you can seek help, if necessary. 
Should your child get sick with a chest infection, then additional tests will be done to try and find out the 
cause of your child’s illness. The tests that will be done will depend on how sick your child is and what the 
illness is. These tests may include: 
1. Blood tests to test for infections, at the time of the illness, and again 4-6 weeks
afterwards
2. A test of the mucus from the nose (nasopharyngeal swab) to test for infection
3 A skin test for tuberculosis infection. 
4 A test of the mucus from the lungs (induced sputum test) for chest infection. 
5 A urine test for smoke exposure 
6 Chest X-ray 
7 Breathing test 
8 A ultrasound test of the lungs 
If your child is enrolled in the study and is admitted to hospital, he/she will be followed up in hospital by 
a member of the study team. The study member will ask you questions about your child’s illness, and 
some tests may be done, including a nose swab and an induced sputum. All of these tests are usual for 
investigating the cause of pneumonia.  
What are the benefits of my child being in the study? 
You and your child will be closely followed for the first few years of your child’s life. Any medical illness or 
problem should be found soon after it develops. Your child’s growth and development will be carefully 
followed. If an illness or problem is found then your child will be promptly investigated and treated. If 
your child gets sick you will be able to take him/ her to your usual health facility, where additional tests 
to find out the cause of your child’s illness may be done, depending on how sick your child is. If your child 
requires hospitalisation, then he/ she will be hospitalised at Paarl hospital as is usually done. If your child 
is hospitalised, then one of the study staff will see your child in hospital and additional investigations may 
be done to try and find out the cause of the illness. Therefore the study offers an opportunity for your 
child to receive appropriate medical care.  The study will also help us to better understand the causes of 
illness in children, and identify the things that may harm their health. We hope that this will lead to 
improvements in child health.  
What are the risks to my child? 
There are no major risks to your child. There may be some discomfort associated with some of the tests 
we will do. These tests are listed below: 
(1) Blood tests
Your child may feel sore when blood samples are taken with a needle. Where possible an 
anaesthetic cream will be used to dull the pain from the needle. Some bruising may occur, but 
this is not harmful and will disappear. Only a small amount of blood (not more than 3 teaspoons) 
will be taken from your child at any time 
(2) Nasopharyngeal swab
A sample of mucus will be taken from your child’s nose, to test for germs that can cause chest 
infections and to monitor which germs are usually in your child’s nose. Your child may experience 
minor discomfort when the nasal swab is done. Occasionally it can cause bleeding from the nose, 
but this is not serious, and usually stops by itself. 
(3) TB skin test
A small injection is made on your child’s arm. This is to test whether your child has TB or not, and 
will be done at regular visits.  Your child will experience minor discomfort due to the needle, with 
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the skin test. There may also be irritation of the skin if the test is positive (reactive). This test will 
need to be checked 2-3 days after the injection is given. 
(4) Induced sputum
Your child will be given salt-water through a nebulizer to loosen the mucous in the lungs. Then a 
sample of that mucus will be suctioned, or your child will be asked to cough up the mucus. Your 
child may experience a little discomfort while the sputum test is done. He/ she may develop 
some coughing or have a small amount of bleeding from the nose after this. These are not 
serious. Occasionally this test can cause the airways of the lungs to close. If this occurs your child 
will be given medicine through an inhaler/nebulizer to open the airways. 
(5) Breathing test
This test is done after a child recovers from pneumonia, and at the 1 year and 2 years visits at 
Paarl Hospital, while your child is asleep and should not cause any discomfort. While your child is 
asleep a mask will be put on his/ her face and the air going in and out of his/ her lungs while 
breathing will be recorded.   
(6) Stool test
This test may be done monthly on your child and then every 6 months after 1 year.   Study staff 
will collect stool from your child’s nappy if passed during a study visit.  If there is no stool 
available, a small tube will be inserted into your child’s bottom and some stool will be sucked out 
with a syringe. The tube is thin and bendable and is only put in 1-2 centimeters to reach stool. 
There is a very small chance of bleeding at the rectum right where the tube goes is.  
(7) Ultrasound test of the lungs
This test will be done if your child develops pneumonia so as to better see how the infection is 
affecting your childs lungs.  This is a very safe procedure and there are no side effects. 
What are the risks to you? 
There are no major risks to you.  Some of the questionnaires ask for sensitive information relating to 
mental health and this may cause some emotional distress or discomfort.  Where significant issues are 
identified, and if you agree, study staff will offer referal to mental health support.  You may also choose 
not to answer certain questions and still remain in the study.  You will be able to take breaks, if you need 
to, and you will be free to terminate or reschedule the interview should the need arise. 
Will I be paid to participate in the study? 
No, you will not be paid to participate in this study.  If you agree to take part, we will reimburse your 
transport costs for visits that are not part of your well child clinic visits. 
Will there be any cost to participate in the study? 
No, there will be no cost to you. 
How long will my child be in the study? 
This consent form is for permission for you and your child to participate in the study from 1 to 2 years of 
age. However, your child will be involved in the study for at least 2 years, with the routine clinic visits, as 
well as hospital visits at 1 year and 2 years of age. Each year we will ask you again to sign permission for 
you and your child to continue in the study for another year. 
Will my child’s participation in the study be confidential? 
All information that you provide will be considered confidential, and no mention of you or your child’s 
name will appear on the stored samples or in any publication in connection with this study. No persons 
other than the health care workers overseeing your child’s care and the study nurses and doctors will 
have access to any information that identifies your child personally.  All your test results will not be 
disclosed to anyone other than for the purpose of treating you if there is a problem. 
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Does my child have to be in the study? 
You can choose not to take part in the study. This will not affect the quality of care your child receives. 
You will be able to decline to participate at any time should any part of the study be unacceptable to you, 
you may still take part in the rest of the study. 
What do I do if I have any questions? 
If you have any questions about this study, you can ask study staff, the Principal Investigator or the lung 
study doctor at: 021 860 2802.  For questions about your rights as a study participant call the Human 
Research Ethics Committee, Faculty of Health Sciences, University of Cape Town, Tel: 021-4066492 
Informed Consent 
1. I, _____________________________ understand the information contained in this consent form, as
explained to me in a language that I understand. I am prepared to participate in this study and 
give consent for my child to participate in this study. 
I agree to allow study staff to access my medical and hospital records as well as those of my child during 
the course of the study. 
2. To be completed by mother:
Child’s Name:____________________________________________________________ 
Mother’s Name:__________________________________________________________ 
Mother’s Signature: _______________________________________________________ 
Date: ___________________________________________________________________ 
3. Study staff providing information: Study staff confirming consent: 
Name: ____________________________ Name: ____________________________ 
Role in Study:_______________________ Role in Study:_______________________ 
Signature: __________________________ Signature: __________________________ 
Date: ______________________________ Date: ______________________________ 
4. If the mother is unable to read or write the entire counselling process must be observed by an
independent witness who can then confirm the procedure once the mother has given consent.
Fingerprint of mother: 
Witness: I confirm that I am independent of the study and that I witnessed the entire enrolment 
counselling process in the home language of the mother. 
Name:________________________________________________________________ 
Signature: _____________________________________________________________ 
Date: ________________________________________________________________ 
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Page 1 of 6POC Chest Ultrasound
Select reader: Attie
Savvas
Karen
David
Enter infant PID:
__________________________________
Scan date:
__________________________________
Pneumonia episode date:
__________________________________
Episode time point: At diagnosis
At follow-up (4-6 weeks)
Start time:
__________________________________
End time:
__________________________________
Scanning / technical difficulties: Yes
No
If yes, please specify: Excessive patient movement
Obesity
Very small infant /neonate
Equipment problem
Other
If equipment problem, please specify:
__________________________________
If other, please specify:
__________________________________
LUNG ULTRASOUND
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Lung ultrasound anatomical zones:
RAU
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
RAL
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
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LAU
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
LAL
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
RPU
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
RPL
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
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Pleural effusion
Pneumothorax
LPU
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
LPL
Yes No Not evaluated
Lung sliding
A-lines
B-lines
Pathological B-lines
Airspace consolidation
Air-bronchograms
Pleural effusion
Pneumothorax
MEDIASTINAL ULTRASOUND
Was a mediastinal ultrasound done? Yes
No
TRANSVERSE views (MT) done? Yes
No
What was the image quality? Adequate
Sub-optimal
Uninterpretable
Was lymphadenopathy present? Yes
No
Not sure
OBLIQUE scan (MO) done? Yes
No
If yes, what was the image quality? Adequate
Sub-optimal
Uninterpretable
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Was lymphadenopathy present? Yes
No
Not sure
Indicate location of adenopathy if present.(See image A
below for lymphnode zones.) B
C
D
E
F
Mediastinal Lymphnode Zones
Conclusion
Image quality: Adequate
Sub-optimal, but interpretable
Uninterpretable
Conclusion: Normal examination
Typical of pneumonia*
Interstitial syndrome**
(* Typical of pneumonia: Airspace consolidation
with or  without air-bronchograms or pleural
effusion. ** Interstitial syndrome: Pathological
B-lines, but no airspace consolidation or pleural
effusion.)
Other pathology: None
Pneumothorax
Pleural effusion
Mediastinal lymphadenopathy
Other
If other, please specify:
__________________________________________
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Additional comment
__________________________________________
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Page 1 of 3WHO CXR Report Form
Select reader: Attie (AS)
Dave (DLR)
Eckart (EVD)
Consensus
CRF completion date:
__________________________________
Infant PID:
__________________________________
Date X-ray taken:
__________________________________
Time of X-ray:
__________________________________
Tick if time not recorded: Not recorded
What is the date of admission / date of the episode? 
__________________________________
What is the nature of this event? Pneumonia
Congenital event (HMD, meconium aspiration, etc)
Other
If 'other' event, please specify:
__________________________________
Is this the initial or a follow-up X-ray? Initial
Follow-up while admitted
Follow up after discharge
Chest X-ray views available: AP
Lateral
Decubitus
((Tick all that are available.))
For the following questions use the WHO standardised radiological pneumonia definitions
below:
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Quality of image: Adequate
Suboptimal
Uninterpretable
Does the film contain significant pathology? Yes
(According to WHO pneumonia scoring system.) No
Unknown
If significant pathology present, please indicate type & location (tick side if present):
RIGHT lung LEFT lung
Primary end-point consolidation:
Other consolidation / infiltrate:
Pleural fluid:
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Conclusion / Interpretation:
Conclusion: Primary end-point consolidation or pleural effusion
Other consolidation / infiltrate
No consolidation / infiltrate / effusion
CXR interpretation (Tick all that apply): Normal
Abscess
Air bronchogram
Alveolar infiltrate
Atelectasis
Bronchial thickening/peribronchial cuffing
Cardiomegaly
Consolidation
Hyperinflation
Interstitial infiltrate
Lymphadenopathy or mass
Pleural effusion
Pneumatocoele
Pneumothorax
Pulmonary edema
Reticulonodular infiltrate
Other
((Tick all that apply):)
If 'other' interpretation / finding, please specify:
__________________________________________
CRF completed by:
__________________________________
Date of reading:
__________________________________
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APPEALS PROCESS
PRODUCTION QUESTIONS
QUESTIONS ABOUT YOUR SUBMISSION
CONTACT THE EDITOR-IN-CHIEF
SCOPE OF JOURNAL
Pediatric Pulmonology publishes the results of original clinical or laboratory research, state of the art
reviews, exceptionally instructive or unique case reports, and letters to the Editor (and responses),
pertaining to the specialty.
Reports on meetings, conferences and symposia may be published after consultation with the Publisher
and the Editor-in-Chief.
Preliminary brief communications will be considered if the articles contain information which would be
considered a major breakthrough in the  eld.
We do not publish research funded by tobacco companies.
As the  eld is continually evolving, our Journal has seen an increase in the number of submissions over
the past few years, and, as a result, our rejection rate is climbing.
PERMISSIONS
No material published in Pediatric Pulmonology may be reproduced or published elsewhere without the
written permission of the publisher and the author. To request permission to reproduce an article, in
part, or in whole, click here to for the Permissions Page
AUTHOR RESOURCES
For additional tools visit Author Services - an enhanced suite of online tools for WileyOnlineLibary journal
authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.
ENGLISH LANGUAGE SERVICES
The Editors reserve the right to return any manuscript that is not in acceptable English. Translations from
another language will not be provided by the Editorial O ce. Authors from countries in which English is
not the primary language should have their manuscript reviewed and corrected by an English language
service before submission. To read more about our policy, and to view a list of editing services, visit:
http://authorservices.wiley.com/bauthor/english_language.asp
GUIDELINES FOR COVER SUBMISSIONS 
If you would like to send suggestions for artwork related to your manuscript to be considered to appear
on the cover of the journal, please follow these general guidelines.
ELECTRONIC SUBMISSION OF MANUSCRIPTS
If you are familiar with our guidelines, click here to login to your ScholarOne account to submit your
manuscript. If you do not have an account, click on “Register Here” to establish one.
MANUSCRIPT GUIDELINES
We accept submissions of the following types of articles. Please note the speci c guidelines for each type:
Original Research Articles
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Original Research Articles should follow the standard structure of abstract, introduction, methods, results,
discussion, and references, and may include up to six tables and/or images when appropriate. Original
Research Articles should be limited to 3,500 words (not including the abstract or references). The abstract
should not exceed 250 words, and references should be limited to forty (40).
Reviews/State of the Art Papers
Editors generally commission Reviews and State of the Art papers, but uninvited submissions are also
welcome, particularly if the submission outlines an important and topical subject with a focus on recent
advances. Reviews should be limited to 4,000 words, while State of the Art papers should be limited to
5,000 words (not including the abstract or references). We ask that the abstracts for these manuscript
types do not exceed 250 words. There is no set limit on images, tables, or references for these types of
manuscripts.
Case Reports
NOTICE TO AUTHORS OF CASE REPORTS: Pediatric Pulmonology is temporarily closing submissions of
Case Reports. We will not consider new case report manuscripts during the period of July 15, 2017 to
October 15, 2017. Case Report submission will re-open on October 15, 2017. 
Pediatric Pulmonology will review case report manuscripts that present unique, paradigm-changing, or
novel accounts of infantile or childhood disorders. Priority for selection for publication will be given to the
following categories:.
1. Novel therapies and outcomes for cystic  brosis
2. Novel disorders or outcomes of ChILD, NEHI, ABCA3 disorders, and surfactant disorders
3. Novel congenital malformations
4. Novel genetic disorders
5. Novel therapies or outcomes for other disorders
There is not a related format for a case series. Manuscripts of this nature will be treated as original
articles or reviews and will compete with other manuscripts in these categories. 
Case reports should be concise (a maximum of 1,000 words, not including the abstract or references), and
contain a maximum of two images and/or tables. The summary/abstract should not exceed 100 words.
Case Reports should contain no more than  ve (5) references. Authorship of case reports shall be limited
to three (3). Physicians who participated in the care, but did not contribute to the writing of the
manuscript may be listed under acknowledgements. Informed consent must be documented. Authors
should note that most accepted Case Reports will be published online only, and not in a print edition.
Editorials (Commentaries)
Editors and members of the Editorial Board may make editorial comments on individual articles or on a
group of articles published in the same issue. Editorials (including pro/con debates) from authors who are
not part of the editorial team are also welcome as submissions to the Journal. These narrowly focused
articles should discuss an article that was recently published, or that is soon to be published. The
commentary should discuss speci c issues within a subject area rather than the whole  eld, while
explaining the implications of the article and putting it in context. Opinions must be factually based.
These types of manuscripts should be limited to 1,500 words (not including the abstract or references).
There is no limitation on the number of tables, images or references for these types of manuscripts.
Letters to the Editors
We encourage letters that o er criticism of published material in an objective, constructive, and
educational manner conducive to further exchanges. Such letters will only be considered if they are in
reference to an article published within the previous six months. Letters may also discuss matters of
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general interest pertaining to the  eld of pediatric pulmonology, or may consist of brief reports of truly
unique cases. Note that we do not publish original, previously unpublished data as letters. If appropriate,
a copy will be sent to the author(s) referred to in the letter, so that they may respond. Letters to the Editor
should not exceed 1,000 words (not including the abstract or references), and may contain a small table
or single image. Letters should contain no more than  ve (5) references.
Top of Page
PRIOR TO SUBMITTING
Prior to submitting a manuscript through ScholarOne, prepare the text and images according to the
instructions found below. You may enter and exit the manuscript submission process at the completion
of each step, and you may save an un nished draft in the system to work on later. However, once you
submit your manuscript though the system, you will not be able to access it for editing. If you have any
questions about this process please contact us at edsupport@wiley.com
We recommend all authors familiarize themselves with the International Committee of Medical Journal
Editors: Uniform Requirements for Manuscripts submitted to Biomedical Journals. Ann Intern Med
1997;126:36-47. The complete text of the document be found online at www.icmje.org
By submitting a manuscript to or reviewing for this publication, your name, email address, and a liation,
and other contact details the publication might require, will be used for the regular operations of the
publication, including, when necessary, sharing with the publisher (Wiley) and partners for production
and publication. The publication and the publisher recognize the importance of protecting the personal
information collected from users in the operation of these services, and have practices in place to ensure
that steps are taken to maintain the security, integrity, and privacy of the personal data collected and
processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-
policy.html.
COMPONENTS OF ARTICLES/FILE PREPARATION
Please make note of the following when preparing your submission:
Main Document
All manuscript types must include a title page, abstract, text and references in the Main Document.
Standard, double-spaced manuscript format, in 12 point font is requested. Number all pages
consecutively.
Title page: The title should be brief (no more than 100 characters in length including spaces) and useful
for indexing. All authors’ names with highest academic degree, a liation of each, but no position or rank,
should be listed. For cooperative studies, the institution where research was primarily done should be
indicated. In a separate paragraph, specify grants, other  nancial support received, and the granting
institutions (grant number(s) and contact name(s) should be indicated on the title page). If support from
manufacturers of products used is listed, assurances about the absence of bias by the sponsor and
principal author must be given. Identify meetings, if any, at which the paper was presented. The name,
complete mailing address, telephone number, fax number, and e-mail address of the person to whom
correspondence and reprint requests are to be sent must be included. Keywords should also be noted on
the title page. For usage as a running head, provide an abbreviated title (maximum 50 characters) on the
bottom of the title page.
Summary/Abstract: In accordance with the structure of the article, with or without separate headings,
outline the objectives, working hypothesis, study design, patient-subject selection, methodology, results
(including numerical  ndings) and conclusions. The Summary should not exceed the word counts outlined
above. If abbreviations are used several times, spell out the words followed by the abbreviations in
parentheses.
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Acknowledgements: Technical assistance, advice, referral of patients, etc. may be brie y acknowledged
at the end of the text under “Acknowledgements.”
Informed Consent: Informed consent statements, if applicable, should be included in the Methods
section.
References/citations: References may be included at the end of your text, or uploaded as a separate  le.
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